Literature DB >> 25253481

Acute onset and rapid progression of multiple organ failure in a young adult with undiagnosed disseminated colonic adenocarcinoma.

Daria Frestad1, Anders Perner2, Ulf Gøttrup Pedersen2.   

Abstract

Colourectal cancer (CRC) is the fourth most common cause of death from cancer worldwide. While rates for CRC in adults age 50 and older have been declining, incidence rates in young adults, a population routinely not screened, has been increasing. We report a rare case of high-grade CRC in a previously healthy 27-year-old man, presented to us with symptoms of increasing abdominal pain and distension. Extensive diagnostic investigation revealed hepatomegaly with multiple processes, signs of vasculitis, extensive liver necrosis, enlarged retroperitoneal and mesenteric lymph nodes, splenomegaly, ascites and multiple vein thrombosis. The patient passed away shortly after admission due to treatment-resistant tumour lysis syndrome and multiple organ failure. Biopsy results revealed disseminated adenocarcinoma of the colon, with metastases to lymph nodes, liver, lungs and pleura. CRC in younger patients tend to present at a later stage and appears to be more aggressive, with a poorer pathological differentiation. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25253481      PMCID: PMC4173146          DOI: 10.1136/bcr-2014-205002

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Colorectal cancer in young adults.

Authors:  Kevin Zbuk; Emma L Sidebotham; Archie Bleyer; Michael P La Quaglia
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

Review 2.  Modifiable risk factors for colon cancer.

Authors:  Edward Giovannucci
Journal:  Gastroenterol Clin North Am       Date:  2002-12       Impact factor: 3.806

3.  Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001.

Authors:  Temeika L Fairley; Cheryll J Cardinez; Jim Martin; Linda Alley; Carol Friedman; Brenda Edwards; Patricia Jamison
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

4.  Colorectal cancer in young patients: characteristics and outcome.

Authors:  P Y Lee; W S Fletcher; E S Sullivan; J T Vetto
Journal:  Am Surg       Date:  1994-08       Impact factor: 0.688

Review 5.  Colorectal cancer in the young.

Authors:  Jessica B O'Connell; Melinda A Maggard; Edward H Livingston; Cifford K Yo
Journal:  Am J Surg       Date:  2004-03       Impact factor: 2.565

6.  Increase in incidence of colorectal cancer among young men and women in the United States.

Authors:  Rebecca L Siegel; Ahmedin Jemal; Elizabeth M Ward
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

Review 7.  Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.

Authors:  Michael B Davidson; Snehal Thakkar; John K Hix; Naveen D Bhandarkar; Alan Wong; Martin J Schreiber
Journal:  Am J Med       Date:  2004-04-15       Impact factor: 4.965

8.  Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome.

Authors:  Márcio Soares; Guilherme A Feres; Jorge I F Salluh
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

9.  Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).

Authors:  Andrea Pession; Fraia Melchionda; Claudia Castellini
Journal:  Biologics       Date:  2008-03
  9 in total
  5 in total

Review 1.  Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

Authors:  Bilal Farooqi; Josh Simmons; Zhonglin Hao
Journal:  J Gastrointest Cancer       Date:  2015-09

2.  Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.

Authors:  Helena S Gouveia; Sílvia O Lopes; Ana Luísa Faria
Journal:  BMJ Case Rep       Date:  2018-03-15

3.  Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review.

Authors:  David Sommerhalder; Amol M Takalkar; Rodney Shackelford; Prakash Peddi
Journal:  Clin Case Rep       Date:  2017-11-13

Review 4.  A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.

Authors:  Mohammad Hossein Yazdi; Mohammad Ali Faramarzi; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  Avicenna J Med Biotechnol       Date:  2015 Oct-Dec

5.  Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC.

Authors:  Xue-Miao Tang; Hao Chen; Qing Li; Yiling Song; Shuping Zhang; Xiao-Shuan Xu; Yiwei Xu; Shulin Chen
Journal:  Onco Targets Ther       Date:  2017-12-28       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.